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Finding the Balance Between Beneﬁts andHarmsWhenUsing Statins
for Primary Prevention of Cardiovascular Disease
AModeling Study
Henock G. Yebyo, MSc; He´le`ne E. Aschmann, MSc; and Milo A. Puhan, MD, PhD
Background: Many guidelines use expected risk for cardiovas-
cular disease (CVD) during the next 10 years as a basis for rec-
ommendations on use of statins for primary prevention of CVD.
However, how harms were considered and weighed against
beneﬁts is often unclear.
Objective: To identify the expected risk above which statins
provide net beneﬁt.
Design: Quantitative beneﬁt–harm balance modeling study.
Data Sources: Network meta-analysis of primary prevention tri-
als, a preference survey, and selected observational studies.
Target Population: Persons aged 40 to 75 years with no history
of CVD.
Time Horizon: 10 years.
Perspective: Clinicians and guideline developers.
Intervention: Low- or moderate-dose statin versus no statin.
Outcome Measures: The 10-year risk for CVD at which statins
provide at least a 60% probability of net beneﬁt, with baseline risk,
frequencies of and preferences for statin beneﬁts and harms,
and competing risk for non-CVD death taken into account.
Results of Base-Case Analysis: Younger men had net beneﬁt
at a lower 10-year risk for CVD than older men (14% for ages 40
to 44 years vs. 21% for ages 70 to 75 years). In women, the risk
required for net beneﬁt was higher (17% for ages 40 to 44 years
vs. 22% for ages 70 to 75 years). Atorvastatin and rosuvastatin
provided net beneﬁt at lower 10-year risks than simvastatin and
pravastatin.
Results of Sensitivity Analysis: Most alternative assumptions
led to similar ﬁndings.
Limitation: Age-speciﬁc data for some harms were not available.
Conclusion: Statins provide net beneﬁts at higher 10-year risks
for CVD than are reﬂected in most current guidelines. In addi-
tion, the level of risk at which net beneﬁt occurs varies consider-
ably by age, sex, and statin type.
Primary Funding Source: Swiss Government Excellence Schol-
arship Ofﬁce, Be´atrice Ederer-Weber Foundation, and North-
South Cooperation at the University of Zurich.
Ann Intern Med. 2019;170:1-10. doi:10.7326/M18-1279 Annals.org
For author afﬁliations, see end of text.
This article was published at Annals.org on 4 December 2018.
Most guidelines recommend statins for primaryprevention of cardiovascular disease (CVD) if 10-
year risk exceeds 7.5% to 10%, often in addition to such
other criteria as high cholesterol level or presence of at
least 1 speciﬁc risk factor (1–5). However, use of statins
for primary prevention of CVD is controversial and var-
ies greatly among countries because of several factors,
such as uncertainty about the applicability of the results
of randomized controlled trials (RCTs) on primary pre-
vention to real-world populations, the deﬁnition of eli-
gible persons likely to beneﬁt, and potential differential
reporting of harms (6–9).
Nevertheless, guidelines must make recommenda-
tions and deal with the uncertainties of the existing ev-
idence base. Guidelines should consider multiple fac-
tors that inﬂuence the balance of beneﬁts and harms of
statins, including preventive effects and harms, base-
line risks for beneﬁt and harm outcomes, and outcome
preferences of persons who may beneﬁt from statins
for primary prevention of CVD (10, 11). However, none
of the current guidelines used a systematic assessment
of the beneﬁt–harm balance of statins that considered
these factors (12). In addition, whether the currently
recommended risk thresholds of 7.5% and 10% are jus-
tiﬁed is unclear. Therefore, this study aimed to assess
the balance of beneﬁts and harms of statins for primary
prevention of CVD and determine age- and sex-speciﬁc
10-year risk thresholds at which the net beneﬁts of st-
atins outweigh the net harms. Because not all statins
have the same beneﬁt and harm proﬁles (13–15), we
analyzed 4 commonly used statins separately.
METHODS
Target Population and Setting
We performed a quantitative beneﬁt–harm balance
modeling study on use of statins for primary prevention
of CVD for persons in the general population aged 40
to 75 years with no history of CVD events. We excluded
persons older than 75 years because of scarce data in
this age group. Our study evaluated the balance of
beneﬁts and harms and accounted for baseline risks for
the beneﬁt and harm outcomes, the magnitude of the
increase or decrease in risk due to statins, the relative impor-
tance of the outcomes, and a speciﬁc time horizon.
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Statins and Beneﬁt and Harm Outcomes
This analysis focused on low- or moderate-dose st-
atins, which are frequently prescribed for primary pre-
vention of CVD (3), and excluded high-dose statins. We
performed the beneﬁt–harm analysis for 4 statins (ator-
vastatin, simvastatin, pravastatin, and rosuvastatin) for
which there were sufﬁcient data from RCTs about their
effects. We selected clinically relevant beneﬁt and harm
outcomes from systematic reviews (14, 16) and quanti-
ﬁed their relevance in a preference-eliciting survey re-
ported elsewhere (17). Beneﬁt outcomes (those favor-
ing statin use) were fatal and nonfatal CVD events.
Harm outcomes (adverse effects of statins) were myop-
athy, hepatic and renal dysfunction, cataracts, hemor-
rhagic stroke, type 2 diabetes, any cancer, nausea or
headache, and treatment discontinuation due to ad-
verse effects. We considered non-CVD mortality as a
competing risk because we found insufﬁcient evidence
that statins reduce deaths due to causes other than
CVD. Although it would be possible to use speciﬁc
CVD events in the beneﬁt–harm balance modeling, we
considered a composite outcome of CVD events as the
end point because most clinical guidelines and risk
scores refer to such a composite outcome. This study
did not consider costs associated with statins.
Data Sources
We systematically selected evidence on the follow-
ing input parameters needed for the quantitative ben-
eﬁt–harm balance modeling (18).
Preventive or Adverse Effects of Statins
We based estimates of statin effects on a network
meta-analysis of CVD events and harm outcomes in a
primary prevention population that we performed pre-
viously for the purpose of the current study (Figures 1
to 3 of the Supplement, available at Annals.org). We
obtained information on preventive effects on cataracts
and hemorrhagic stroke from 2 RCTs (HOPE-3 [Heart
Outcomes Prevention Evaluation-3] [19] and MEGA
[Management of Elevated Cholesterol in the Primary
Prevention Group of Adult Japanese] [20], respectively)
because there were not enough trials for a meta-
analysis. Data on harm outcomes from trials might be
incomplete because of short follow-up or limited exter-
nal validity or may be affected by differential reporting
bias (8, 21). Observational studies may be more suit-
able for providing real-world estimates of harms, but
they are often inherently biased (8, 21). We thus con-
sidered combined statin effect estimates for the harm
outcomes from large observational studies and RCTs
using a Bayesian inverse variance–weighted averaging
method (Appendix Table 1 [available at Annals.org]
and Table 1 of the Supplement) (22–25). The preven-
tive effects from observational studies contributed less
to the pooled effect due to higher variances. We also
performed a sensitivity analysis using estimates of statin
effects on harms from RCTs only.
Baseline Outcome Risks in the Population
Population-based baseline risks are favored over
event rates in control groups of RCTs because they bet-
ter reﬂect the real-world population (18). We extracted
age- and sex-speciﬁc baseline rates of type 2 diabetes,
any cancer, hemorrhagic stroke, and non-CVD mortality
from Global Burden of Disease estimates for Switzer-
land (26) and rates of myopathy, renal and hepatic dys-
function, and cataracts from other observational data
(age- or country-speciﬁc rates were not available for
these) (23) (Table 2 of the Supplement). We chose Swit-
zerland for some of these age- and sex-speciﬁc risks
because the weights of the outcomes were elicited
there and because outcome risks are moderate there,
except for competing risk for death, which is low com-
pared with other countries. However, we also per-
formed the analysis for the United States and the
United Kingdom (see Sensitivity Analyses). Because
baseline risks for nausea or headache and treatment
discontinuation were not available, we used rates from
control groups of RCTs.
Outcome Preferences
We considered population average preference
weights from a preference-eliciting study designed to
inform the current study. The best–worst scaling survey
elicited preferences for beneﬁt and harm outcomes of
statins from a primary prevention population in Switzer-
land and Ethiopia (17). We considered preference
weights reported as the surface under the cumulative
ranking curve (SUCRA) (analyzed using a network meta-
analytic approach) for the base-case analysis (27) and
additional preference scales, including best–worst
score and log-odds, for sensitivity analyses. The SUCRA
indicates the probability of an outcome that patients
would rather avoid or a weight showing the relative
importance of an outcome to patients (larger values
correspond to more important outcomes) (Appendix
Table 2, available at Annals.org).
Time Horizon
Although data from RCTs are available for follow-up
less than 5 years, we extended the time horizon to 10
years with the assumption of smaller CVD risk accumula-
tion and similar effects of statins over the period in low- to
moderate-risk persons.
Subgroups
We modeled the balance of beneﬁts and harms
and determined risk thresholds for 350 subgroups ac-
cording to age and sex across 10-year CVD risks rang-
ing from 1% to the value above which the beneﬁts con-
sistently outweighed the harms. We did not need to
predict 10-year CVD risks because we repeated the
analysis for each percentage point increase up to 25%
(all statins) or 40% (speciﬁc statins). Although not rele-
vant to this study, the use of well-calibrated risk scores
is important for clinical practice to determine a person's
risk and whether this risk justiﬁes use of statins.
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Statistical Analysis
Beneﬁt–Harm Balance Index
We used a beneﬁt–harm balance model devel-
oped by Gail and colleagues at the National Cancer
Institute (NCI) (28, 29) and extended it to ﬁt our re-
search question of determining risk thresholds. A de-
tailed description of our model is provided in the Ap-
pendix (available at Annals.org). In brief, we estimated
the expected age- and sex-speciﬁc number of beneﬁt
and harm outcome events per 1000 persons not using
statins over 10 years by using an exponential model
that assumed constant risk rates over the time horizon
and accounted for competing risk for non-CVD death.
We then calculated the corresponding number of ex-
pected events for each outcome among statin recipi-
ents by using the same model but with consideration of
estimates of statin effects. The differences in expected
events with and without statin use provided attributable
absolute events for each beneﬁt and harm outcome.
We then weighted the differences by their respective
preference weights and summed them to yield a single
beneﬁt–harm index. The resulting index could have any
negative (harms outweighed beneﬁts), zero (harms
equaled beneﬁts), or positive (beneﬁts outweighed
harms) value on an arbitrary scale. To account for sta-
tistical uncertainty of the input parameters, we re-
peated the analysis 100 000 times for each subgroup
with resampling of the parameters independently from
normal distributions deﬁned by their mean estimates
(log risk ratio, SUCRA, and baseline risks) and their SEs.
Determining 10-Year Risk Thresholds for Net Beneﬁts
We calculated the probability of net beneﬁts as the
proportion of repetitions for which the beneﬁt–harm in-
dex was positive (beneﬁts outweighed harms). This
probability could have any value between 0% and
100%. We deﬁned statins as having net beneﬁts if the
probability of the index exceeding zero was at least
60% and net harms if the probability was less than 40%.
Thus, probabilities of at least 40% but less than 60%
(assuming an arbitrary 10% probability of uncertainty
instead of deﬁning the cutoff at exactly 50%) repre-
sented neither net beneﬁts nor net harms. The proba-
bilities were computed across the spectrum of CVD
risks, from which we could identify risk thresholds for
different subgroups. We performed all analyses using
R, version 3.3.2 (R Foundation for Statistical Comput-
ing) (30).
Sensitivity Analyses
We performed sensitivity analyses using different
alternative assumptions. We tested the effect that dif-
ferent preference weights, including log-odds from a
conditional logit model and best–worst scores, had on
the balance of beneﬁts and harms (17). We repeated
the analysis with statin effects on harms from RCTs only
instead of convergent estimates from RCTs and obser-
vational data. We checked whether excluding RCTs in
high-risk primary prevention populations and consider-
ing baseline risks from the United States and the United
Kingdom affected the balance of beneﬁts and harms.
We also tested the assumption of a constant risk rate
over 10 years by using a piecewise exponential model
(31). Although it is reasonable to assume constant risk
for CVD events over 10 years (and most prediction
models for CVD events do so), risk for some harms may
change over time. In particular, the data used in our
meta-analyses (not shown) suggested that risks for
headache or nausea, myopathy, and renal and hepatic
dysfunction may be highest at treatment initiation and
decrease constantly over time. Therefore, we used a
1-year time horizon in each piecewise exponential
model for these outcomes where we allowed the risk
rates to decrease by 10% per year. Finally, the out-
comes are not independent of each other, but we
could not ﬁnd data showing empirical correlations
among them. Thus, we tested the effect on the risk
thresholds by assuming moderate to strong correlation
between CVD and diabetes and between diabetes and
renal dysfunction. The correlations we used are proba-
bly too strong, but we decided to err on the side of
caution to avoid underestimating the effect of correla-
tions among outcomes (Figure 5 of the Supplement).
Ethics
This study was based on published and aggre-
gated data for which no ethical approval was needed.
Role of the Funding Source
The Swiss Government Excellence Scholarship Of-
ﬁce, the Be´atrice Ederer-Weber Foundation, and the
North-South Cooperation at the University of Zurich
had no role in the design or conduct of the study or the
decision to submit the manuscript for publication.
RESULTS
Expected Number of Beneﬁt and Harm
Outcome Events
Tables 1 and 2 show the expected number of ben-
eﬁt and harm outcome events per 1000 men and
women over 10 years with and without use of all statins.
The expected number of events among persons not
using statins increased for diabetes, any cancer, and
hemorrhagic stroke due to age, whereas the increase in
these events in the statin group was due to the effect of
statins in addition to age. The increase in events with
age in the statin and nonstatin groups accounted for
the competing risk for non-CVD death, whose effect on
attenuation of the outcome risks was smaller than the
effect of age on risk for diabetes, any cancer, and hem-
orrhagic stroke. There was no increase in myopathy,
cataracts, or renal and hepatic dysfunction with age be-
cause we had to rely on average estimates given that
age-speciﬁc estimates were not available; instead, risks
decreased slightly with age due to the competing risk.
The differences in expected events between men and
women resulted from differences in baseline risks for
the outcomes, differential statin effects on some out-
comes, and higher competing risk for death in men.
Tables 1 and 2 also show the expected number of CVD
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events for each percentage point increase in CVD risk
with and without statins.
Beneﬁt–Harm Balance and Risk Thresholds
We estimated the beneﬁt–harm balance by sex and
age group across 10-year CVD risk of 1% to 25% for all
statins and 1% to 40% for speciﬁc statins until we ob-
tained a probability above which the balance was con-
sistently positive. Figure 1 shows the probabilities at
which statins provide net beneﬁt among 350 sub-
groups based on age and sex (mean beneﬁt–harm bal-
ance indices are presented in Figure 4 of the Supple-
ment). Statins demonstrated net beneﬁts (green cells)
starting at a CVD risk of 14% for men aged 40 to 44
years, and the threshold increased to 21% for those
aged 70 to 75 years. Similar results were observed for
women, but the risk thresholds were higher (17% for
women aged 40 to 44 years and 22% for those aged 70
to 75 years). Persons at high risk for CVD (>21%) were
likely to beneﬁt from statins, regardless of sex or age.
Figures 2 and 3 illustrates the probabilities at which
the beneﬁts of speciﬁc statins outweighed the harms
for 2240 subgroups based on age, sex, and CVD risk.
As a result of differences in preventive effects on ben-
eﬁt or harm outcomes, atorvastatin had the most favor-
able beneﬁt–harm balance, followed by rosuvastatin,
especially for persons with low or medium CVD risk and
age less than 60 years. The other statins did not dem-
onstrate beneﬁts at the same risk level for any of the
age groups. For example, among men aged 45 to 49
years, net beneﬁts were seen at a 10-year CVD risk of
15% for atorvastatin but at risk levels of 18% for rosuv-
astatin, 19% for pravastatin, and 21% for simvastatin.
Table 1. Number of Expected Beneﬁt and Harm Outcome Events per 1000 Men in Switzerland Over 10 Years With and
Without Use of Statins*
Variable Aged 40–44
Years
Aged 45–49
Years
Aged 50–54
Years
Aged 55–59
Years
Aged 60–64
Years
Aged 65–69
Years
Aged 70–75
Years
No
Statins
Statins No
Statins
Statins No
Statins
Statins No
Statins
Statins No
Statins
Statins No
Statins
Statins No
Statins
Statins
Harm outcomes
Myopathy 4 5 4 5 4 5 4 5 3 5 3 5 3 4
Renal dysfunction 7 10 7 10 7 10 7 9 7 9 7 9 7 9
Hemorrhagic stroke 3 3 5 6 6 7 7 9 10 12 14 16 22 26
Hepatic dysfunction 24 34 24 34 24 33 24 33 23 33 23 32 22 32
Type 2 diabetes 28 30 34 37 45 49 59 64 65 70 61 66 50 54
Any cancer 16 16 26 26 48 49 84 86 138 141 200 204 239 244
Cataracts 94 122 94 121 93 121 92 120 92 119 90 117 88 114
Headache/nausea 334 367 333 366 332 364 329 362 326 358 321 353 314 345
Treatment
discontinuation
295 296 295 295 293 294 291 292 288 289 284 285 278 278
10-y CVD risk
1% 10 7 10 7 10 7 10 7 10 7 10 7 9 7
2% 20 15 20 15 20 15 20 15 19 14 19 14 19 14
3% 30 22 30 22 30 22 29 22 29 22 29 21 28 21
4% 40 30 40 30 40 29 39 29 39 29 38 28 37 28
5% 50 37 50 37 49 37 49 37 49 36 48 36 47 35
6% 60 45 60 44 59 44 59 44 58 43 57 43 56 42
7% 70 52 70 52 69 52 69 51 68 51 67 50 65 49
8% 80 60 79 59 79 59 78 59 78 58 76 57 75 56
9% 90 67 89 67 89 67 88 66 87 65 86 64 84 63
10% 100 75 99 75 99 74 98 74 97 73 96 72 93 70
11% 110 82 109 82 109 82 108 81 107 80 105 79 103 77
12% 119 90 119 90 119 89 118 89 117 88 115 86 112 84
13% 129 97 129 97 129 97 128 96 126 95 124 94 121 91
14% 139 105 139 105 138 104 137 104 136 103 134 101 131 99
15% 149 113 149 113 148 112 147 111 146 110 143 108 140 106
16% 159 121 159 120 158 120 157 119 155 118 153 116 150 113
17% 169 128 169 128 168 127 167 126 165 125 163 123 159 120
18% 179 136 179 136 178 135 177 134 175 133 172 131 168 128
19% 189 144 189 143 188 143 187 142 185 140 182 138 178 135
20% 199 152 199 151 198 151 196 149 194 148 191 145 187 142
21% 209 159 209 159 208 158 206 157 204 155 201 153 196 150
22% 219 167 219 167 218 166 216 165 214 163 210 161 206 157
23% 229 175 228 175 227 174 226 173 223 171 220 168 215 164
24% 239 183 238 183 237 182 236 180 233 179 230 176 225 172
25% 249 191 248 190 247 190 245 188 243 186 239 183 234 179
CVD = cardiovascular disease.
* Values are the predicted number of events with and without use of statins per 1000 men over 10 y based on participants' baseline risks, calculated
using an exponential model and adjusted for non-CVD mortality as a competing risk. Some outcomes, such as myopathy, hepatic dysfunction, and
renal dysfunction, had restrictive deﬁnitions in the observational data source (i.e., only moderate or serious cases were reported) and were average
estimates (i.e., not age-speciﬁc).
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With the exception of atorvastatin, the risk thresholds
for the speciﬁc statins were all higher than for the over-
all statins due to differences in preventive effects and
less precision (wider distributions) in the speciﬁc statins
that could have led to greater variation in randomly
sampled estimates during modeling and accordingly
wider distributions of the resulting beneﬁt–harm indi-
ces.
Sensitivity Analyses
Results of the sensitivity analyses are presented in
Figures 6 to 13 of the Supplement. Most showed
thresholds similar to those estimated in the base-case
analysis, with deviation of 0% or 1% (except U.S. men
and women aged 55 to 59 years, who had 3% to 4%
higher thresholds). However, the sensitivity analyses
with the log-odds (not normalized) and with harm ef-
fects from RCTs only showed similar patterns (increases
with age and in women), but with 3% to 4% lower risk
thresholds (Figures 7 and 12 of the Supplement).
DISCUSSION
To our knowledge, this is the ﬁrst quantitative
beneﬁt–harm balance modeling study on statins for pri-
mary prevention of CVD and the ﬁrst study to deter-
mine 10-year risk thresholds above which the beneﬁts
outweigh the harms over 10 years. We found that st-
atins are likely to provide net beneﬁts at substantially
higher risk thresholds than the 7.5% to 10% thresholds
to which most guidelines refer. Depending on age and
sex, the risk thresholds varied between 14% and 22%.
The thresholds were lower for atorvastatin and rosuvas-
Table 2. Number of Expected Beneﬁt and Harm Outcome Events per 1000 Women in Switzerland Over 10 Years With and
Without Use of Statins*
Variable Aged 40–44
Years
Aged 45–49
Years
Aged 50–54
Years
Aged 55–59
Years
Aged 60–64
Years
Aged 65–69
Years
Aged 70–75
Years
No
Statins
Statins No
Statins
Statins No
Statins
Statins No
Statins
Statins No
Statins
Statins No
Statins
Statins No
Statins
Statins
Harm outcomes
Myopathy 3 4 3 4 3 4 3 4 3 4 3 4 3 4
Renal dysfunction 6 8 6 8 6 8 6 7 6 7 6 7 6 7
Hemorrhagic stroke 3 3 5 5 6 7 7 8 8 10 11 13 18 21
Hepatic dysfunction 24 34 24 34 24 34 24 34 24 33 24 33 23 33
Type 2 diabetes 21 22 22 24 29 32 42 45 48 52 48 52 41 45
Any cancer 24 24 38 39 52 53 70 71 91 93 116 118 131 134
Cataract 161 204 161 204 160 203 160 202 159 201 157 199 155 196
Headache/nausea 334 367 334 367 333 366 331 364 330 362 326 359 322 354
Treatment
discontinuation
296 297 295 296 294 295 293 294 291 292 289 289 285 286
10-y CVD risk
1% 10 7 10 7 10 7 10 7 10 7 10 7 10 7
2% 20 15 20 15 20 15 20 15 20 15 19 14 19 14
3% 30 22 30 22 30 22 30 22 29 22 29 22 29 21
4% 40 30 40 30 40 30 39 29 39 29 39 29 38 29
5% 50 37 50 37 50 37 49 37 49 37 49 36 48 36
6% 60 45 60 45 60 44 59 44 59 44 58 43 57 43
7% 70 52 70 52 69 52 69 52 69 51 68 51 67 50
8% 80 60 80 60 79 59 79 59 79 59 78 58 77 57
9% 90 67 90 67 89 67 89 67 88 66 87 66 86 65
10% 100 75 100 75 99 74 99 74 98 74 97 73 96 72
11% 110 82 109 82 109 82 109 82 108 81 107 80 105 79
12% 120 90 119 90 119 90 119 89 118 89 117 88 115 87
13% 130 98 129 97 129 97 128 97 128 96 126 95 125 94
14% 140 105 139 105 139 105 138 104 137 104 136 103 134 101
15% 150 113 149 113 149 112 148 112 147 111 146 110 144 109
16% 160 121 159 120 159 120 158 120 157 119 156 118 153 116
17% 170 128 169 128 169 128 168 127 167 126 165 125 163 124
18% 180 136 179 136 179 136 178 135 177 134 175 133 173 131
19% 189 144 189 144 189 143 188 143 187 142 185 140 182 138
20% 199 152 199 152 198 151 198 150 196 149 195 148 192 146
21% 209 160 209 159 208 159 207 158 206 157 204 156 201 154
22% 219 168 219 167 218 167 217 166 216 165 214 163 211 161
23% 229 175 229 175 228 175 227 174 226 173 224 171 221 169
24% 239 183 239 183 238 182 237 182 236 180 233 179 230 176
25% 249 191 249 191 248 190 247 189 246 188 243 187 240 184
CVD = cardiovascular disease.
* Values are the predicted number of events with and without use of statins per 1000 women over 10 y based on participants' baseline risks,
calculated using an exponential model and adjusted for non-CVD mortality as a competing risk. Some outcomes, such as myopathy, hepatic
dysfunction, and renal dysfunction, had restrictive deﬁnitions in the observational data source (i.e., only moderate or serious cases were reported)
and were average estimates (i.e., not age-speciﬁc).
Balance of Beneﬁts and Harms When Using Statins for Prevention of CVD ORIGINALRESEARCH
Annals.org Annals of Internal Medicine • Vol. 170 No. 1 • 1 January 2019 5
Downloaded from http://annals.org by Univ of California Davis user on 01/03/2019
tatin than for simvastatin and pravastatin across all age
groups and for men and women, indicating that they
had a more favorable beneﬁt–harm balance.
Our results suggest that higher 10-year risk thresh-
olds for prescription of statins may be warranted than
what current guidelines recommend and that the
thresholds vary considerably by age, sex, and statin
type. Guidelines emphasize beneﬁts, and although
harms are not ignored, they seem to have little effect
on recommendations (12). The problem with such an
approach is that eligibility for statins increases with age
because more events can be prevented in elderly per-
sons who are at higher CVD risk, as a recent study
showed (32). However, when harm outcomes, which
also increase with age, are considered, the beneﬁt–
harm balance of statins becomes less favorable. In-
deed, our results show that the thresholds of 10-year
CVD risk above which statins provide more beneﬁts
than harms are higher in elderly than younger persons.
Precautions must be taken when prescribing statins to
older persons, especially those older than 65 years, be-
cause the 10-year risk prediction models are heavily
inﬂuenced by age (33), which is a nonmodiﬁable risk
factor, and thus many in this age group may be eligible
for statins even in the absence of other risk factors, such
as hyperlipidemia (34, 35). The small differences in risk
thresholds between men and women were due to vari-
ation in baseline risk for other outcomes, such as dia-
betes, any cancer, and cataracts, as well as the differen-
tial effect of statins on myopathy and renal dysfunction.
The sensitivity analyses testing different assump-
tions demonstrated similar risk thresholds (Figure 14 of
the Supplement). Some of these thresholds were
slightly higher and others were slightly lower than the
results of the base-case analysis, but all, including the
analyses that considered treatment effects of harms
from RCTs only, showed higher thresholds than those
commonly recommended by guidelines. Most of our
analyses also showed that harm outcomes had less ef-
fect on the balance of beneﬁts and harms because of
small statin effects or smaller preference weights. How-
ever, our models probably still underestimated the risk
thresholds because of potentially unmeasured harms
(such as rhabdomyolysis or neurologic effects), rela-
tively low baseline risks for some harm outcomes due
to restrictive deﬁnitions (reporting of only moderate or
serious cases) in our data sources, and unavailability of
age-speciﬁc risks for these outcomes, which would
make statins even less favorable for older persons.
Redeﬁning the risk thresholds would have impor-
tant clinical implications. Current practice indicates sta-
tin use for a large proportion of the healthy population.
For example, on the basis of the Copenhagen General
Population Study (32), 31% to 44% (depending on the
guideline) of persons aged 40 to 75 years would be
eligible for statins for primary prevention at a 10-year
Figure 1. Probabilities at which statin therapy for primary prevention of CVD is likely to provide net beneﬁts among 350
subgroups based on age, sex, and CVD risk (1% to 25%).
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CVD risk of 10%. However, the proportion would be
substantially smaller if our age-, sex-, and statin-speciﬁc
recommendations were followed, especially if pravasta-
tin and simvastatin, for which our model showed higher
risk thresholds, were recommended. More beneﬁts were
demonstrated with atorvastatin and rosuvastatin; these
had lower risk thresholds due to differences in their effect
on CVD and some harm outcomes. These results are con-
sistent with the fact that atorvastatin and rosuvastatin have
more potent pharmacologic properties in reducing cho-
lesterol levels than the other statins (15).
Although the importance of shared decision making
in clinical practice is well known, none of the guidelines
refer to a decision aid for fully informed decisions (6). Our
Figure 2. Probabilities at which statin therapy for primary prevention of CVD is likely to provide net beneﬁts among 1120
subgroups of men based on age, CVD risk (1% to 40%), and statin type.
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granulated risk heat maps could be a ﬁrst step toward
promoting patient-centered decision making combined
with valuable clinical judgment and experience. Our
model assumed average age- and sex-speciﬁc baseline
risks for the harm outcomes, but this could be individual-
ized and integrated into interactive decision aids or elec-
tronic medical records to incorporate individual-patient
preferences and baseline risks for the outcomes to pre-
dict a personalized beneﬁt–harm balance (11). For exam-
ple, a woman with no net beneﬁts (based on average
population preferences) at a 10-year CVD risk of 15%may
have net beneﬁts if she places a higher value on CVD or a
lower value on harm outcomes or if she has a lower risk
for harms than the general population. Thus, additional
Figure 3. Probabilities at which statin therapy for primary prevention of CVD is likely to provide net beneﬁts among 1120
subgroups of women based on age, CVD risk (1% to 40%), and statin type.
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studies may be required to test the sensitivity of the
thresholds to individual-patient preferences as well as to
assess the effect of the new thresholds on perceived
health status, such as quality of life.
Our study has limitations that must be considered
when interpreting the results. We did not test how the
risk thresholds changed across varying risks for harm
outcomes (as we did for the different CVD risk levels);
instead, we took age- and sex-speciﬁc average risks
from population data. We were unable to obtain
enough data on all possible harms and age-speciﬁc
data on some harm outcomes, so the risk thresholds we
determined may still be too low. In addition, the bal-
ance of beneﬁts and harms might change if different
countries were considered, but we would expect the
thresholds to be similar or higher because Switzerland
has moderate risks for the harm outcomes. To apply
our ﬁndings, valid and well-calibrated CVD risk predic-
tion models that are context-speciﬁc are needed. The
risk scores for fatal CVD only used by the guideline
from the European Society of Cardiology and the Euro-
pean Atherosclerosis Society cannot be used because
we considered the risks for fatal and nonfatal CVD
events combined (36). Another limitation is that al-
though studies show that preferences do not signiﬁ-
cantly vary by age or sex or across populations (17, 37),
our study did not extensively examine whether the ben-
eﬁt–harm balance is preference-sensitive, which would
indicate the need for individualized decision-making
tools to determine the balance of beneﬁts and harms.
Finally, our ﬁndings apply to low- and moderate-dose
statins only.
In conclusion, our results suggest that guidelines
should use higher 10-year risk thresholds when recom-
mending statins for primary prevention of CVD and
should consider different recommendations based on
sex, age group, and statin type. Such recommenda-
tions would substantially improve selection of persons
eligible for statin therapy for primary prevention of
CVD.
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APPENDIX: TECHNICAL DETAILS
This appendix describes the statistical approach
used for the beneﬁt–harm balance modeling and sum-
marizes the input data. Details on data use are pro-
vided in the Supplement.
Beneﬁt–Harm Balance Modeling
We used an approach developed by Dr. Mitchell
Gail at the NCI in the context of a beneﬁt–harm assess-
ment for tamoxifen for prevention of breast cancer (28).
The beneﬁt–harm balance indices for each risk combi-
nation according to sex, age, and 10-year CVD risk
were calculated using the Gail/NCI approach based on
an exponential model as described in the following
equations:
Expected number of events without statin use
(Ni,no statins) per 1000 persons over 10 years, taking into
consideration baseline risk for each outcome (Ii) and
competing risk for non-CVD death (M).
Ni,no statins 1000IiIiM1 exp10 yrsIiM
(1)
Expected number of events with statin use (Ni,statins)
per 1000 persons over 10 years, taking into consider-
ation baseline risk (Ii) and treatment effect of statins on
each outcome (RR) and competing risk for non-CVD
death (M).
Ni,statins 1000RRi IiRRi IiM
1 exp10 yrsRRi IiM (2)
The beneﬁt–harm balance index for a given sub-
group was obtained from the cumulative difference of
the number of events between the treatment and con-
trol groups (calculated using equations 1 and 2) for
each outcome and weighted by the respective weights
that reﬂect patient preferences (Wi).
Benefit–harm index 
i
10 outcomes
Ni,no statinsNi,statinsWi
(3)
To account for the statistical uncertainty of the in-
put parameters, we resampled each estimate of the in-
put parameters 100 000 times from normal distribu-
tions deﬁned by their mean estimates (log risk ratio, log
rate, and SUCRA) and their SEs. From the distribution of
the resulting beneﬁt–harm index, we determined the
probability above which the beneﬁt–harm index was
positive for at least 60% (an example is provided in the
Appendix Figure). We performed this calculation for a
range of 10-year CVD risks (1% to 25% for statins as a
class and 1% to 40% for speciﬁc statins) and identiﬁed
the threshold at which the net beneﬁts outweighed the
net harms.
Example of the Gail/NCI Approach
The beneﬁt–harm balance modeling was based on
distributions of the input parameters. However, to illus-
trate the method, we present a manually calculated ex-
ample with speciﬁc parameter values for 1 beneﬁt end
point (CVD outcome) and 1 harm outcome (diabetes)
for 1 subgroup to answer the question, “Do men aged
55 to 59 years with risk for CVD of 10% over 10 years
beneﬁt from statins?” We assumed that statins did not
have other harm risks. The risk for death due to causes
other than CVD in this age group is 0.0038 person-
year, which is considered a competing risk in the
model.
The expected number of CVD events without use
of statins, calculated with equation 1, is:
NCVD,no statin 10000.01050.0105 0.0038
1 exp100.0105 0.0038 97.8. (4)
This shows that men aged 55 to 59 years would be
expected to have 97.8 CVD events per 1000 persons in
10 years if they did not take statins. Of note, the 10%
probability of having CVD over 10 years was converted to
0.0105 person-year using the equation (1n[1  p])/t
(where t is the time horizon and p is the 10-year risk) to
convert the probability to a rate (because, for example, a
10% 10-year risk does not equate to a 1% probability in 1
year).
The corresponding number of events after statin
use (risk ratio of statins reducing CVD events is 0.74),
calculated with equation 2, is:
NCVD,statin 10000.74 0.01050.74 0.0105
 0.00381 exp100.74 0.0105 0.0038
 73.4. (5)
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The same cohort of men aged 55 to 59 years would
be expected to have 73.4 CVD events if they were
treated with statins for 10 years. Thus, taking statins for
10 years could prevent 24.4 CVD events per 1000 per-
sons (97.8  73.4). It is then important to consider pa-
tient preferences (that is, the preference for taking st-
atins to obtain particular beneﬁts at the price of having
certain risk for harms due to statins). Accordingly, 24.4
CVD events × 0.645 (preference value for CVD) yields
15.7 preference-adjusted CVD events prevented, which
is used in the beneﬁt–harm balance model.
Similarly, the expected numbers of diabetes cases
with and without statin use are:
Ndiabetes,no statin 10000.00620.0062 0.0038
1 exp100.0062 0.0038 59.0. (6)
Ndiabetes,statin 10001.09 0.00621.09 0.0062
 0.00381 exp101.09 0.0062 0.0038
 64.3. (7)
More than 5 diabetes cases per 1000 persons
(59.0  64.3 = 5.3) that are attributable to preventive
statin treatment are expected to occur over 10 years.
The preference-adjusted rate of diabetes cases is 1.35
per 1000 persons (5.3 diabetes cases × 0.255 [prefer-
ence value for diabetes]).
In this example, the beneﬁt–harm balance (or net
beneﬁt) is 14.35 prevented events (15.7 CVD events 
1.35 diabetes cases).
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Appendix Table 2. Preference Weights for Beneﬁt and Harm Outcomes Considered for the Beneﬁt–Harm Balance Modeling*
Outcome SUCRA (95% CI) Best–Worst Score Log-Odds (95% CI)
Myopathy 0.255 (0.253–0.256) 0.138 0.60 (0.37–0.83)
Renal dysfunction 0.262 (0.242–0.293) 0.110 0.67 (0.42–0.92)
Hemorrhagic stroke 0.766 (0.644–0.818) 0.582 3.75 (3.43–4.60)
Hepatic dysfunction 0.378 (0.347–0.424) 0.289 1.45 (1.20–1.69)
Type 2 diabetes 0.47 (0.350–0.531) 0.304 1.51 (1.25–1.75)
Any cancer 0.859 (0.843–0.880) 0.779 4.37 (4.03–4.71)
Cataracts 0.378 (0.347–0.424) 0.289 1.45 (1.20–1.69)
Nausea/headache 0.065 (0.035–0.105) 0.042 0.23 (0.0–0.47)
Treatment discontinuation 0.085 (0.002–0.141) 0.000 0.00†
CVD 0.645 (0.553–0.692) 0.518 3.20 (2.85–3.46)
CVD = cardiovascular disease; SUCRA = surface under the cumulative ranking curve.
* Based on reference 17. The outcome preferences were elicited using a best–worst scaling survey in Switzerland and Ethiopia in which participants
were asked to select 2 answers (most worrisome and least worrisome outcomes concurrently) from a different set of outcomes arranged using a
balanced incomplete block design (17). The data were analyzed using different methods and thus presented in different scales, including SUCRA,
standardized best–worst score, and log-odds. The SUCRA resulted from a multiple treatment comparison method (i.e., network meta-analysis)
approach. The best–worst score was the difference in frequency at which an outcome was selected as most worrisome or least worrisome. Similarly,
the log-odds was analyzed using a conditional logit model and was a measure of relative importance showing the odds that the selected outcome
was the most worrisome given a set of other outcomes. The 3 measures are relative preference values indicating which outcomes patients would
rather avoid. Higher values indicate more worrisome or more important outcomes to patients. The SUCRA was used for the base-case analysis,
whereas best–worst score and log-odds were used for the sensitivity analyses. This study elicited preferences for the different harm outcomes and
speciﬁc CVD events. We then assigned the preference for the composite outcome of CVD events from the preference values of speciﬁc CVD
outcomes.
† Reference outcome in the conditional logit model.
Appendix Figure. Distribution of beneﬁt–harm indices of
statins for men aged 55 to 59 y across different CVD risks.
Benefit–Harm Indices Across Predicted
10-y CVD Risk of 1% to 25%
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The ﬁgure demonstrates how the distributions of beneﬁt–harm bal-
ance indices across the range of 10-y risks for CVD of 1% to 25% shift
from negative to zero and to positive, with men aged 55 to 59 y used
as an example. The vertical line shows the risk threshold at which the
probability of net beneﬁts is ≥60%. CVD = cardiovascular disease.
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